pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
canakinumab
Phase 3 · small molecule · Non-small Cell Lung Cancer
canakinumab for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Internal code CACZ885U2301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Non-small Cell Lung Cancer
- Status
- terminated
- Trials
- 2